Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion

Oncogene volume 25, pages 4300–4309 (2006)Cite this article

Abstract

Malignant pleural effusion (MPE) is a poor prognostic sign for patients with non-small-cell lung cancer (NSCLC). The generation of MPE is largely regulated by vascular endothelial growth factor (VEGF), and upregulation of VEGF by Stat3 has been observed in several types of tumor cells. In this study, we demonstrate constitutively activated Stat3 in several human lung cancer cell lines and in tumor cells infiltrated in the pleurae of patients with adenocarcinoma cell lung cancer (ADCLC) and MPE. The observations suggest that activated Stat3 plays a role in the pathogenesis of ADCLC. In PC14PE6/AS2 cells, a Stat3-positive human ADCLC cell line, autocrine IL-6 activated Stat3 via JAKs, not via Src kinase. PC14PE6/AS2 cells express higher VEGF mRNA and protein than do Stat3-negative PC14PE6/AS2/dnStat3 cells. In an animal model, PC14P6/AS2/dnStat3 cells produced no MPE and less lung metastasis than did PC14P6/AS2 cells. PC14PE6/AS2 cells also expressed higher VEGF protein, microvessel density, and vascular permeability in tumors than did PC14P6/AS2/dnStat3 cells. Therefore, we hypothesize that autocrine IL-6 activation of Stat3 in ADCLC may be involved in the formation of malignant pleural effusion by upregulating VEGF. Higher levels of IL-6 and VEGF were also found in the pleural fluids of patients with ADCLC than in patients with congestive heart failure. The autocrine IL-6/Stat3/VEGF signaling pathway may also be activated in patients with ADCLC and MPE. These findings provide novel targets for the management of MPE.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Alexandrakis MG, Coulocheri SA, Bouros D, Mandalaki K, Karkavitsas N, Eliopoulos GD . (2000). Oncol Rep 7: 1327–1332.

  • Anderson CB, Philpott GW, Ferguson TB . (1974). Cancer 33: 916–922.

  • Bihl M, Tamm M, Nauck M, Wieland H, Perruchoud AP, Roth M . (1998). Am J Resp Cell Mol Biol 19: 606–612.

  • Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C et al. (1999). Cell 98: 295–303.

  • Buettner R, Mora LB, Jove R . (2002). Clin Cancer Res 8: 945–954.

  • Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M et al. (1996). Nature 380: 435–439.

  • Dvorak HF, Brown LF, Detmar M, Dvorak AM . (1995). Am J Pathol 146: 1029–1039.

  • Fernandes A, Hamburger AW, Gerwin BI . (1999). Int J Cancer 83: 564–570.

  • Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS et al. (1996). Nature 380: 439–442.

  • Hoffman PC, Mauer AM, Vokes EE . (2000). Lancet 355: 479–485.

  • Hoheisel G, Izbicki G, Roth M, Chan CH, Reichenberger F, Schauer J et al. (1998). Respiration 65: 183–186.

  • Hung TL, Chen FF, Liu JM, Lai WW, Hsiao AL, Huang WT et al. (2003). Clin Cancer Res 9: 2605–2612.

  • Hutchins D, Steel CM . (1994). Int J Cancer 58: 80–84.

  • Kishimoto T, Akira S, Taga T . (1992). Science 258: 593–597.

  • Levy DE, Darnell Jr JE . (2002). Nat Rev Mol Cell Biol 3: 651–662.

  • Memon A, Zawadzki ZA . (1981). Curr Probl Cancer 5: 1–30.

  • Mesiano S, Ferrara N, Jaffe RB . (1998). Am J Pathol 153: 1249–1256.

  • Naito T, Satoh H, Ishikawa H, Yamashita YT, Kamma H, Takahashi H et al. (1997). Anticancer Res 17: 4743–4746.

  • Nakajima K, Yamanaka Y, Nakae K, Kojima H, Ichiba M, Kiuchi N et al. (1996). EMBO J 15: 3651–3658.

  • Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J et al. (2002). Oncogene 21: 2000–2008.

  • Okamoto M, Lee C, Oyasu R . (1997). Cancer Res 57: 141–146.

  • Seki Y, Suzuki N, Imaizumi M, Iwamoto T, Usami N, Ueda Y et al. (2004). Int J Oncol 24: 931–934.

  • Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF . (1983). Science 219: 983–985.

  • Siegsmund MJ, Yamazaki H, Pastan I . (1994). J Urol 151: 1396–1399.

  • Song L, Turkson J, Karras JG, Jove R, Haura EB . (2003). Oncogene 22: 4150–4165.

  • Sugiura S, Ando Y, Minami H, Ando M, Sakai S, Shimokata K . (1997). Clin Cancer Res 3: 47–50.

  • Takayama K, Ueno H, Nakanishi Y, Sakamoto T, Inoue K, Shimizu K et al. (2000). Cancer Res 60: 2169–2177.

  • Turkson J . (2004). Expert Opin Ther Targets 8: 409–422.

  • Wei LH, Kuo ML, Chen CA, Chou CH, Lai KB, Lee CN et al. (2003). Oncogene 22: 1517–1527.

  • Wells J, Boyd KE, Fry CJ, Bartley SM, Farnham PJ . (2000). Mol Cell Biol 20: 5797–5807.

  • Yamaguchi T, Kimura H, Yokota S, Yamamoto Y, Hashimoto T, Nakagawa M et al. (2000). Jpn J Clin Oncol 30: 53–58.

  • Yano S, Herbst RS, Shinohara H, Knighton B, Bucana CD, Killion JJ et al. (2000a). Clin Cancer Res 6: 957–965.

  • Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM et al. (2000b). Am J Pathol 157: 1893–1903.

  • Yokoyama A, Maruyama M, Ito M, Kohno N, Hiwada K, Yano S . (1992). Chest 102: 1055–1059.

  • Yu H, Jove R . (2004). Nat Rev Cancer 4: 97–105.

  • Zebrowski BK, Yano S, Liu W, Shaheen RM, Hicklin DJ, Putnam Jr JB et al. (1999). Clin Cancer Res 5: 3364–3368.

Download references

Acknowledgements

This work was supported by grants 91-B-FA09-1-4 from the Ministry of Education Program to Promote Academic Excellence in Universities, and NSC 93-2314-B-006-035.

Author information

Authors and Affiliations

  1. Institute of Basic Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan

    H-H Yeh, H-S Liu & W-C Su

  2. Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University, Tainan, Taiwan

    H-H Yeh & H-S Liu

  3. Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

    W-W Lai

  4. Department of Radiotherapy, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

    H H W Chen

  5. Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

    W-C Su

Authors
  1. H-H Yeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W-W Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H H W Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H-S Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W-C Su
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to H-S Liu or W-C Su.

Additional information

Supplementary Information accompanies the paper on Oncogene website (http://www.nature.com/onc).

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yeh, HH., Lai, WW., Chen, H. et al. Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Oncogene 25, 4300–4309 (2006). https://doi.org/10.1038/sj.onc.1209464

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209464

Keywords

This article is cited by

Search

Advanced search

Quick links